Cape Investment Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Cape Investment Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.3K	Hold	800	–	–	﹤0.01%	1147
2026 Q2	$2.94K	Buy	+800	New	+$2.66K	﹤0.01%	1157
2025 Q4	–	Sell	-350	Closed	-$1.71K	–	1333
2025 Q3	$1.71K	Hold	350	–	–	﹤0.01%	698
2025 Q2	$1.77K	Hold	350	–	–	﹤0.01%	963
2025 Q1	$1.85K	Sell	350 -154	-31%	-$1.12K	﹤0.01%	904
2024 Q4	$3.41K	Buy	504 +154	+44%	+$1.03K	﹤0.01%	813
2024 Q3	$2.31K	Hold	350	–	–	﹤0.01%	807
2024 Q2	$2.63K	Hold	350	–	–	﹤0.01%	765
2024 Q1	$3.49K	Hold	350	–	–	﹤0.01%	706
2023 Q4	$3.45K	Buy	+350	New	+$2.5K	﹤0.01%	838
2023 Q3	–	Sell	-250	Closed	-$1.87K	–	942
2023 Q2	$1.87K	Hold	250	–	–	﹤0.01%	779
2023 Q1	$1.67K	Buy	+250	New	+$1.98K	﹤0.01%	831

Other funds holding RXRX

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

WWM

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

AWM

Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

TWM

TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Cape Investment Advisory's RXRX Position: Q3 2026 in Review

Cape Investment Advisory held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 800 shares worth $3.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

Cape Investment Advisory first reported a position in RXRX in Q1 2023 and has held it in 12 quarters since. The position peaked at $3.49K in Q1 2024. 22 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

Cape Investment Advisory held 800 shares of Recursion Pharmaceuticals worth $3.3K as of Q3 2026.
Cape Investment Advisory left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Cape Investment Advisory's portfolio in Q3 2026, its #1147 holding.
Cape Investment Advisory first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Cape Investment Advisory's Recursion Pharmaceuticals position peaked at $3.49K in Q1 2024.
22 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Cape Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.